Artykuł powstał we współpracy z Sandoz Polska Sp. z o.o. SPEAK/MED/61/06-2020
ABSTRACT
Diagnostic and therapeutic management of Turner syndrome
Turner syndrome is a genetic syndrome in girls associated with complete or partial monosomy of chromosome X that is present in all or only some cell lines. The consequences include a short stature and abnormalities in the course of sexual maturation. It is estimated that 80-100 neonates are diagnosed with Turner syndrome in Poland annually. The wide range of health problems encountered in individuals with Turner syndrome means that they need to have access to multispeciality medical care.
This article describes the clinical presentation of Turner syndrome and discusses the phenotype-karyotype correlation. A short stature is seen in 95-100% of patients with Turner syndrome, making it the most prominent manifestation. Accordingly, much space in the article is devoted to the strategy for treating short stature, and particularly the use of recombinant growth hormone in hormone therapy to improve adult body height. The author also proposes a scheme for monitoring patients with Turner syndrome on the basis of the relevant literature and her own experience.
Piśmiennictwo
1. Gravholt CH, Andersen NH, Conway GS, et al.; International Turner Syndrome Consensus Group. Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. Eur J Endocrinol 2017;177(3):G1-70
2. Hankus M, Sołtysik K, Szeliga K, et al. Prediction of spontaneous puberty in Turner syndrome based on mid-childhood gonadotropin concentrations, karyotype and ovary visualization: a longitudinal study. Horm Res Paediatr 2018;89(2):90-7
3. Mazzanti L, Cicognani A, Baldazzi L, et al. Gonadoblastoma in Turner syndrome and Y-chromosome-derived material. Am J Med Genet 2005;135:150-4
4. Cools M, Drop SL, Wolffenbuttel KP, et al. Germ cell tumors in the intersex gonad: old paths, new directions, moving frontiers. Endocr Rev 2006;27:468-84
5. Leppig KA, Sybert VP, Ross JL, et al. Phenotype and X inactivation in 45,X/46,X,r(X) cases. Am J Med Genet A 2004;128A(3):276-84
6. Wolff DJ, Van Dyke DL, Powell CM; Working Group of the ACMG Laboratory Quality Assurance Committee. Laboratory guideline for Turner syndrome. Genet Med 2010;12(1): 52-5
7. Davenport ML. Approach to the patient with Turner syndrome. J Clin Endocrinol Metab 2010;95:1487-95
8. Donaldson M, Kriström B, Ankarberg-Lindgren C, et al.; on behalf of the European Society for Paediatric Endocrinology Turner Syndrome Working Group. Optimal pubertal induction in girls with Turner syndrome using either oral or transdermal estradiol: a proposed modern strategy. Horm Res Paediatr 2019;91(3):153-63
9. Węgiel M, Antosz A, Gieburowska J, et al. Autoimmunity predisposition in girls with Turner syndrome. Front Endocrinol (Lausanne) 2019;10:511
10. Gawlik AM, Berdej-Szczot E, Blat D, et al. Immunological profile and predisposition to autoimmunity in girls with Turner syndrome. Front Endocrinol (Lausanne) 2018;9:307
11. Ministerstwo Zdrowia. Załącznik B.42. Leczenie niskorosłych dzieci z zespołem Turnera. https://www.gov.pl/attachment/24fb030d-07ac-44a5-afbb-866296323384. Dostęp 5.10.2020
12. Gawlik A, Gawlik T, Małecka-Tendera E i wsp. Wpływ nasilenia fenotypu na czas rozpoznawania zespołu Turnera. Pediatr Endocrinol 2006;5(2):23-30
13. Savendahl L, Davenport ML. Delayed diagnosis of Turner’s syndrome: proposed guidelines for change. J Pediatr 2000;137:455-9
14. Stephure DK; Canadian Growth Hormone Advisory Committee. Impact of growth hormone supplementation on adult height in turner syndrome: results of the Canadian randomized controlled trial. J Clin Endocrinol Metab 2005;90(6):3360-6
15. Ross JL, Quigley CA, Cao D, et al. Growth hormone plus childhood low-dose estrogen in Turner’s syndrome. N Engl J Med 2011;364(13):1230-42
16. Darendeliler F, Karagiannis G, Wilton P. Headache, idiopathic intracranial hypertension and slipped capital femoral epiphysis during growth hormone treatment: a safety update from the KIGS database. Horm Res 2007;68(Suppl 5):41-7
17. Bell J, Parker KL, Swinford RD, et al. Long-term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab 2010;95(1):167-77
18. Bolar K, Hoffman AR, Maneatis T, et al. Long-term safety of recombinant human growth hormone in turner syndrome. J Clin Endocrinol Metab 2008;93(2):344-51
19. Tuffli GA, Johanson A, Rundle AC, et al. Lack of increased risk for extracranial, nonleukemic neoplasms in recipients of recombinant deoxyribonucleic acid growth hormone. J Clin Endocrinol Metab 1995;80(4):1416-22
20. Menke LA, Sas TC, de Muinck Keizer-Schrama SM, et al. Efficacy and safety of oxandrolone in growth hormone-treated girls with Turner syndrome. J Clin Endocrinol Metab 2010;95(3):1151-60
21. Gault EJ, Perry RJ, Cole TJ, et al. Effect of oxandrolone and timing of pubertal induction on final height in Turner’s syndrome: randomised, double blind, placebo controlled trial. BMJ 2011;342:d1980